Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program
CAMBRIDGE, Mass., June 14, 2020 /PRNewswire/ -- Sanofi and Sobi(TM), together with the World Federation of Hemophilia (WFH) and WFH USA, today announced an extension of their support of the WFH Humanitarian Aid Program with an additional donation of up to 500 million IUs of factor therapy for humanitarian use, fulfilling the 2014 pledge to donate up to an unprecedented 1 billion IUs over a ten-year period. Since the initial pledge to donate their medicine to the program, over 450 million IUs have been provided and over 17,200 people with hemophilia have been treated with factor donated by Sanofi and Sobi between 2015 and 2019. Additionally, the companies will continue to provide financial support for initiatives such as treatment, access and education programs for a period up to five years,
"Through this partnership with Sanofi and Sobi, our Founding Visionary Contributors, we have been able to significantly expand the reach of the WFH Humanitarian Aid Program, which is leading to a paradigm shift in the management of hemophilia in areas with limited or no access to treatment and care," said Alain Baumann, Chief Executive Officer, World Federation of Hemophilia. "With their continued support, we are confident that people with hemophilia in these countries will continue to receive much needed treatment that is both predictable and sustainable - the foundation of the WFH Humanitarian Aid Program. Our vision at WFH is treatment for all."
Significant unmet need in developing world
More than 75% of people with hemophilia have limited or no access to diagnosis and treatment, particularly in the developing world. People with severe hemophilia in these countries often do not survive to adulthood; those who do, often face a life of severe disability, isolation and chronic pain. The underlying physical and psychological toll of hemophilia can be significant without reliable access to care.
"Patients are at the center of all that we do, and our support of the WFH Humanitarian Aid Program, together with Sobi, builds on Sanofi Genzyme's legacy of helping patients around the world have access to the treatments they need," said Bill Sibold, Executive Vice President and Head of Sanofi Genzyme. "In the past five years, we have seen the life-changing impact a reliable supply of factor therapy can have for people in developing countries; access to prophylactic treatment for children, corrective surgeries, all helping to reduce the burden of this disease. We are honored to play our role in providing hope to those patients and families most in need."
"For lasting change to become a reality, we need to recognize that access to treatment is a fundamental human right. We are proud to do our part to address this critical health issue, in partnership with Sanofi," said Guido Oelkers, CEO and President at Sobi. "Partnership in reaching the goals is essential. We are pleased to see others following our lead and encourage more companies to join in the shift that the WFH and their local organizations have made possible and that we together can carry forward. Only through a broad long-term commitment to increase awareness, knowledge and access to treatments will the effect of our donation be sustainable and withstanding."
The WFH Humanitarian Aid Program has over the years made significant improvements in providing access to care. A predictable supply of factor therapy is essential to improving treatment and care. In addition, education programs for treaters and patients are critical initiatives helping to develop in-country capacities to improve diagnosis and treatment monitoring; all of which are needed to create a sustainable treatment environment which lead to better outcomes for patients. Sanofi and Sobi's continued support of the WFH Humanitarian Aid Program for up to five more years, provides for a potential total contribution up to 1 billion IUs of extended half-life factor therapy for a period up to ten years, with the continued opportunity to address the treatment gap and raise the standard of care in the developing world.
A far-reaching impact on hemophilia care
With the provision of a consistent supply of factor, corrective surgeries and prophylaxis treatment for young children have become possible. Since initial shipments of Sanofi and Sobi medicines to the WFH Humanitarian Aid Program began, the impact has been far reaching. Through 2019:
-- 450 million IUs of clotting factor have treated over 17,200 people in 42
countries
-- 900 children under the age of 10 are receiving prophylaxis treatment
-- More than 160,000 acute bleeds have been treated
-- More than 2,300 surgeries have taken place including those that were
life- and limb-saving
Sanofi and Sobi believe all patients should have access to the treatment they need regardless of where they live.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer, our Visionary Contributor; Grifols and Roche, our Leadership Contributors; and our Contributor, CSL Behring. The WFH and WFH USA collaborate to manage and control the WFH Humanitarian Aid Program. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org
About Sobi
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenues amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Sanofi Media Relations
Sanofi Investor Relations
Nicolas Kressmann
Felix Lauscher
Tel: +1 (732) 532-5318
Tel.: +33 (0)1 53 77 45 45
Nicolas.Kressmann@sanofi.com
ir@sanofi.com
Sobi Media Relations
Sobi Investor Relations
Linda Holmström
Paula Treutiger
+ 46 708 734 095
+ 46 733 666 599
linda.holmstrom@sobi.com
paula.treutiger@sobi.com
Sanofi forward looking statements:
This press release contains forward-
looking statements as defined in the
Private Securities Litigation Reform
Act of 1995, as amended. Forward-
looking statements are statements
that are not historical facts. These
statements include projections and
estimates and their underlying
assumptions, statements regarding
plans, objectives, intentions and
expectations with respect to future
financial results, events,
operations, services, product
development and potential, and
statements regarding future
performance. Forward-looking
statements are generally identified
by the words "expects",
"anticipates", "believes",
"intends", "estimates", "plans" and
similar expressions. Although
Sanofi's management believes that
the expectations reflected in such
forward-looking statements are
reasonable, investors are cautioned
that forward-looking information
and statements are subject to
various risks and uncertainties,
many of which are difficult to
predict and generally beyond the
control of Sanofi, that could cause
actual results and developments to
differ materially from those
expressed in, or implied or
projected by, the forward-looking
information and statements. These
risks and uncertainties include
among other things, the
uncertainties inherent in research
and development, future clinical
data and analysis, including post
marketing, decisions by regulatory
authorities, such as the FDA or the
EMA, regarding whether and when to
approve any drug, device or
biological application that may be
filed for any such product
candidates as well as their
decisions regarding labelling and
other matters that could affect the
availability or commercial potential
of such product candidates, the fact
that product candidates if approved
may not be commercially successful,
the future approval and commercial
success of therapeutic alternatives,
Sanofi's ability to benefit from
external growth opportunities, to
complete related transactions and/
or obtain regulatory clearances,
risks associated with intellectual
property and any related pending or
future litigation and the ultimate
outcome of such litigation, trends
in exchange rates and prevailing
interest rates, volatile economic
and market conditions, cost
containment initiatives and
subsequent changes thereto, and the
impact that COVID-19 will have on
us, our customers, suppliers,
vendors, and other business
partners, and the financial
condition of any one of them, as
well as on our employees and on the
global economy as a whole. Any
material effect of COVID-19 on any
of the foregoing could also
adversely impact us. This situation
is changing rapidly and additional
impacts may arise of which we are
not currently aware and may
exacerbate other previously
identified risks. The risks and
uncertainties also include the
uncertainties discussed or
identified in the public filings
with the SEC and the AMF made by
Sanofi, including those listed under
"Risk Factors" and "Cautionary
Statement Regarding Forward-Looking
Statements" in Sanofi's annual
report on Form 20-F for the year
ended December 31, 2019. Other than
as required by applicable law,
Sanofi does not undertake any
obligation to update or revise any
forward-looking information or
statements.
Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
View original content to download multimedia:http://www.prnewswire.com/news-releases/sanofi-and-sobi-donate-up-to-500-million-additional-ius-of-clotting-factor-to-wfh-humanitarian-aid-program-301076510.html
SOURCE Sanofi
